Your session is about to expire
← Back to Search
Pembrolizumab + Chemotherapy for Bile Duct Cancer (KEYNOTE-966 Trial)
KEYNOTE-966 Trial Summary
This trial is testing a new combination therapy for biliary tract cancer. The hypothesis is that the new therapy will improve overall survival compared to the current standard of care.
KEYNOTE-966 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKEYNOTE-966 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183KEYNOTE-966 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with specific immune therapy for cancer.I have had treatment for advanced biliary tract cancer.You are expected to live for more than 3 months.I can provide a sample of my tumor for testing.My organs are functioning well.I have or might have cancer spread to my brain or spinal cord.I have received an organ or tissue transplant from another person.I have cancer of the ampulla of Vater.My cancer is not small cell, neuroendocrine, lymphoma, sarcoma, mixed histology, or mucinous cystic.My cancer is in the bile ducts or gallbladder and cannot be removed by surgery.If you have had hepatitis B or hepatitis C in the past, you may still be eligible to participate as long as you meet the other requirements of the study.
- Group 1: Arm A (Pembrolizumab+Gemcitabine+Cisplatin)
- Group 2: Arm B (Placebo+Gemcitabine+Cisplatin)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it dangerous to use Pembrolizumab?
"Pembrolizumab has been studied in multiple Phase 3 trials, meaning that there is evidence of its efficacy and safety. Our analysts have given it a score of 3."
Could you list some of the other research studies that have used Pembrolizumab?
"Pembrolizumab is being researched in 1893 clinical trials, with 424 of those trials currently in Phase 3. Pembrolizumab is being studied all over the world, with a large concentration in Shanghai, but with research centres in 77337 locations."
At how many institutions is this research project taking place?
"23 different hospitals are running this clinical trial at the moment. The locations of these facilities are in Oklahoma City, Charleston, Hamilton and 20 other cities. If you decide to participate in this research, try to enroll at a hospital that is close to your home to reduce the amount of travel required."
Pembrolizumab is used to treat which medical conditions?
"Pembrolizumab is a common treatment for refractory, relapsed mediastinal large b-cell lymphoma. Pembrolizumab has also shown to be effective in treating other forms of cancer, such as urinary bladder, advanced testicular, and small cell lung cancer (sclc)."
Share this study with friends
Copy Link
Messenger